All In Biotech

Free tool

FAERS Monitor: Mekinist

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217513 or its brand name (Mekinist, Trametinib, Trametinib Dimethyl Sulfoxide). Reports on generic versions are filed under their own applications.

Reports

24,319

Serious

17,696

73% of reports

Hospitalization

6,629

Death reported

5,169

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia4,116
  • death3,413
  • malignant neoplasm progression2,070
  • rash1,764
  • fatigue1,538
  • nausea1,512
  • diarrhoea1,308
  • chills1,303
  • product use in unapproved indication1,091
  • vomiting1,083
  • off label use873
  • headache771
  • asthenia745
  • drug ineffective686
  • malaise658

Reports by year received

View as table
YearReports
2013360
2014628
20151,693
20161,422
20171,760
20182,350
20192,676
20202,470
20212,414
20222,233
20232,150
20241,731
20251,525
2026907

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal2,07017.817.132,344
pyrexiaSignal4,11610.410.135,122
chillsSignal1,3039.79.210,114
product use in unapproved indicationSignal1,0913.83.62,285
rashSignal1,7643.53.43,218
deathSignal3,4133.43.36,119
vomiting1,0832.01.9547
diarrhoea1,3081.81.7436
asthenia7451.71.6225
fatigue1,5381.71.6469
nausea1,5121.71.6404
malaise6581.31.246
headache7711.11.03
off label use8730.90.820
drug ineffective6860.40.4491

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.